Ashley Losier, MD
Pulmonary Disease · New Haven, CTNPI 1871934661
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (49.5%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 6 manufacturers reported payments, led by Mannkind Corporation at 31.6% of the total. 2025 is the largest year on record at $10,134, more than ten times the $199 reported in 2019.
Across 11 payments — averaging $1064.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Mannkind Corporation$4K
- Boehringer Ingelheim$3K
- Inogen, Inc.$2K
- Insmed, Inc.$2K
- Electromed, Inc.$1K
- Genentech USA, Inc.$100
Across 17 payments — averaging $9498.52 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sanofi US Services Inc.$96K
- Mannkind Corporation$57K
- Insmed, Inc.$8K
What the payments were for
- Consulting fees$5,42846%
- Speaking & faculty fees$5,80050%
- Food & beverage$2802%
- Education$1992%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Mannkind Corporation | 2 | $3,704 |
| Boehringer Ingelheim | 4 | $2,676 |
| Inogen, Inc. | 1 | $2,200 |
| Insmed, Inc. | 2 | $1,827 |
| Electromed, Inc. | 1 | $1,200 |
| Genentech USA, Inc. | 1 | $100 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$11,707 in reported general payments places this provider in the 80th percentile of 255 pulmonary disease providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 73 | $61,502 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 90 | $53,633 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 63 | $40,222 |
| Spiriva HandihalerTiotropium Bromide | 32 | $22,370 |
| Breo ElliptaFluticasone/Vilanterol | 24 | $13,671 |
| Spiriva RespimatTiotropium Bromide | 12 | $10,500 |
| Rifabutin | 21 | $4,858 |
| Fluticasone-Salmeterol HfaFluticasone Propion/Salmeterol | 11 | $3,544 |
| SymbicortBudesonide/Formoterol Fumarate | 13 | $3,130 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 141 | $2,822 |
| Ethambutol Hcl | 45 | $1,776 |
| Ventolin HfaAlbuterol Sulfate | 27 | $1,524 |
| Levalbuterol Tartrate HfaLevalbuterol Tartrate | 14 | $758 |
| Fluticasone Propionate | 27 | $536 |
| Rifampin | 16 | $534 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimStiolto Respimat, Spiriva Respimat | $2,676 | $64,133102 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 255 pulmonary disease providers in Connecticut.
Other pulmonary disease in New Haven
- Geoffrey ChuppNew Haven$1.2M
- Michael ImevboreNew Haven$323K
- Naftali KaminskiNew Haven$180K
- Lauren CohnNew Haven$134K
- Erica HerzogNew Haven$74K
- Mridu GulatiNew Haven$53K
- Jennifer PossickNew Haven$48K
- Carolyn RochesterNew Haven$29K
- Maor SaulerNew Haven$18K
- Jonathan KoffNew Haven$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.